SI-BONE's Sacroiliac Joint Implant Show Accelerated Fusion, Reduction In Opioid Use

  • SI-BONE Inc SIBN has announced the publication of 2-year results from the SALLY study of the iFuse-3D Implant System. 
  • Clinical results at 24 months showed marked and sustained improvements in the sacroiliac (SI) joint pain, patient function, and quality of life.
  • Results also exhibited a significant reduction in the proportion of study subjects taking opioids for SI joint pain (59% at baseline to 18% at 24 months). 
  • The study also included three objective physical function tests (active straight leg raise, five times sit-to-stand, and transitional timed up-and-go), all of which showed statistically significant improvements from baseline.
  • An earlier publication of 12-month results from SALLY reported radiographic analysis of CT scans showing 100% of treated SI joints showed bone integration to the iFuse-3D implant surface, and 77% of treated joints showed bony bridging across the joint.
  • The iFuse-3D implant is a 3D-printed triangular titanium implant designed for the fusion of the SI joint. 
  • The 3D-printed surface with enhanced porosity mimics cancellous bone and allows for enhanced bone ongrowth and ingrowth.
  • Price Action: SIBN shares closed at $28.83 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareSmall CapGeneralBriefsOpioid
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!